Abstract Library

#4511 Sequencing chemotherapy and radiotherapy leading to complete remission in a patient with highly aggressive, advanced neuroendocrine cancer of unknown origin

Introduction: Neuroendocrine neoplasms arise from endocrine cells throughout the body, primary tumour may be localised in various organs. Neuroendocrine carcinoma (NEC) is very aggressive form of these tumours with survival limited usually to a few months despite oncological treatment.

Conference:

Presenting Author: Hajac �

Authors: Szymańska P, Hajac L, Chowaniec Z, Marzec R, Sokołowski M,

Keywords: neuroendocrine cancer, radiotherapy, oligometastatic disease,

#4500 Effectiveness of palbociclib plus letrozole as first line therapy of metastatic breast neuroendocrine carcinoma: A case report

Introduction: Palbociclib plus endocrine therapy is the standard treatment of advanced luminal breast cancer. However, we lack data on its effectiveness in breast neuroendocrine carcinoma (NEC).

Conference:

Presenting Author:

Authors: Saidi M, Aris H, Elyebdri H, Ilham L,

Keywords: breast neuroendocrine carcinoma, CDK4/6 inhibitor, palbociclib, endocrine therapy,

#4457 Primary mixed hepatocellular carcinoma-neuroendocrine carcinoma: A case report

Introduction: Mixed epithelial neoplasms (MiNENs) are characterised by the coexistence of neuroendocrine and non-neuroendocrine components within a single tumour, each discernible histologically and immunohistochemically, with a minimum tumour proportion of 30%. Primary hepatic MiNENs are exceedingly rare entities.

Conference:

Presenting Author: Tang Y

Authors: Wang Y, Wang R, Yi X, Guo M, Tang Y,

Keywords: pancreatic neuroendocrine tumour, functional, parathyroid hormone related peptide,

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#4404 A comparative study on the progression of neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms

Introduction: The prognostic differences between neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) remain unclear.

Conference:

Presenting Author:

Authors: Duan X, Yin F,

Keywords: mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), neuroendocrine carcinoma (NEC), disease progression, treatment protocol, signalling pathway,